ATE136909T1 - Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest - Google Patents

Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Info

Publication number
ATE136909T1
ATE136909T1 AT90910699T AT90910699T ATE136909T1 AT E136909 T1 ATE136909 T1 AT E136909T1 AT 90910699 T AT90910699 T AT 90910699T AT 90910699 T AT90910699 T AT 90910699T AT E136909 T1 ATE136909 T1 AT E136909T1
Authority
AT
Austria
Prior art keywords
pct
complement activation
antibody
hinge region
complement
Prior art date
Application number
AT90910699T
Other languages
English (en)
Inventor
Terje Michaelsen
Inger Sandlie
Original Assignee
Dynal As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal As filed Critical Dynal As
Application granted granted Critical
Publication of ATE136909T1 publication Critical patent/ATE136909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Image Processing (AREA)
  • Closed-Circuit Television Systems (AREA)
  • Burglar Alarm Systems (AREA)
  • Alarm Systems (AREA)
AT90910699T 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest ATE136909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898916400A GB8916400D0 (en) 1989-07-18 1989-07-18 Modified igg3

Publications (1)

Publication Number Publication Date
ATE136909T1 true ATE136909T1 (de) 1996-05-15

Family

ID=10660201

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90910699T ATE136909T1 (de) 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Country Status (8)

Country Link
US (1) US5348876A (de)
EP (1) EP0483194B1 (de)
JP (1) JPH05500303A (de)
AT (1) ATE136909T1 (de)
DE (1) DE69026615T2 (de)
DK (1) DK0483194T3 (de)
GB (1) GB8916400D0 (de)
WO (1) WO1991001335A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1746107B1 (de) 1998-04-02 2014-12-17 Genentech, Inc. Antikörpervarianten und deren Fragmente
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6193892B1 (en) 1999-03-03 2001-02-27 Promega Corporation Magnetic separation assembly and method
JP2003531149A (ja) * 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
ES2305886T3 (es) * 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
US8309318B2 (en) * 2004-02-10 2012-11-13 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1674479A1 (de) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PL2573114T3 (pl) * 2005-08-10 2016-10-31 Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
EP1999470A4 (de) * 2006-03-10 2009-08-19 Macrogenics Inc Identifizierung und herstellung von antikörpern mit variierenden schweren ketten und anwendungsverfahren dafür
GB2436616A (en) 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (de) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2008002933A2 (en) * 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008007159A1 (en) * 2006-07-14 2008-01-17 Eötvös Lorand University Measurement of complement activation products on antigen arrays
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
WO2009123894A2 (en) * 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US20110081347A1 (en) * 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
EP2826789A1 (de) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten Region eines Antikörpers
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (de) 2010-03-04 2019-05-22 MacroGenics, Inc. Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FR2609398A1 (fr) * 1988-04-19 1988-07-15 Zagyansky Yuly Structure de l'igg plus antigene et complement, ses mecanismes et les consequences importantes
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies

Also Published As

Publication number Publication date
WO1991001335A1 (en) 1991-02-07
US5348876A (en) 1994-09-20
EP0483194B1 (de) 1996-04-17
JPH05500303A (ja) 1993-01-28
DE69026615D1 (de) 1996-05-23
DE69026615T2 (de) 1996-09-26
DK0483194T3 (da) 1996-05-13
GB8916400D0 (en) 1989-09-06
EP0483194A1 (de) 1992-05-06

Similar Documents

Publication Publication Date Title
ATE136909T1 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
ES2119369T3 (es) Dispositivo sensor para un ensayo sandwich.
DE68911674D1 (de) Testverfahren und reagenzsatz dazu.
KR940005957A (ko) 항-글리코헤모글로빈 단일클론 항체 및 글리코헤모글로빈의 측정 방법
DE58902586D1 (de) Immunoassay und -rolymere igg-derivate zur kompensation von stoerfaktoren in immunoassays.
ATE118275T1 (de) Immunoassayverfahren zum nachweis von antigenen.
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
DE3883073D1 (de) Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel.
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
DE69106002D1 (de) Testverfahren und reagenziensatz dafür.
DE69124511D1 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
FR2708348B1 (fr) Procédé de dosage d'une substance immunologique au moyen de particules de latex magnétiques et de particules non-magnétiques.
Van Toorenenbergen et al. IgG4 and release of histamine from human peripheral blood leukocytes
BR9507389A (pt) Método para detectar a presença de uma espécie mycobacterium e um kit e anticorpos para uso no mesmo
KR930008462A (ko) 치주질환과 관련된 미생물의 검증방법에서 높은 pH에서의 추출로 단백질을 보호하는 용도 및 이에 유용한 키트
ATE188551T1 (de) Feststellung von antikörperproduktion
DE3686717D1 (de) Immuntestverfahren.
ATA261687A (de) Laktoferrin enthaltendes inkubationsmedium für festphasen-immunometrische verfahren und seine verwendung
Reid et al. Biological and chemical differences among proteins having reaginic activity
KR900017549A (ko) 암의 혈청진단법
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
DK608789D0 (da) Cea-immunanalyse uden falske positive foraarsaget af humant anti-museantistof
PT81050B (pt) Anticorpo monoclonal anti-urocinase e processo para a preparacao de composicoes de materia de teste biologicos que o utilizam
ATE249627T1 (de) Vorrichtung und test zur bestimmung eines antigens oder eines antikörpers in einer testprobe
WALLER Serological studies of enzymatically fragmented IgG globulins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee